Publications by authors named "Megan Mazzei"
Article Synopsis
- - The RAS family GTPases are a key group of oncogenes frequently mutated in human cancers, with mutations found in about 20% of tumors, particularly NRAS mutations present in about 25% of melanomas.
- - Current therapies have targeted KRAS mutations effectively, but there is a significant lack of treatments specifically aimed at NRAS, making it a critical area for developing new cancer therapies.
- - This study introduces a new monobody that can bind to both forms of NRAS and inhibit its signaling, offering a promising direction for creating selective inhibitors and potential therapeutics for NRAS and BRAF-mutant melanomas.
Mutations in one of the three RAS genes (HRAS, KRAS, and NRAS) are present in nearly 20% of all human cancers. These mutations shift RAS to the GTP-loaded active state due to impairment in the intrinsic GTPase activity and disruption of GAP-mediated GTP hydrolysis, resulting in constitutive activation of effectors such as RAF. Because activation of RAF involves dimerization, RAS dimerization has been proposed as an important step in RAS-mediated activation of effectors.
View Article and Find Full Text PDFEvaluation of Genome Sequences of the Bacteriophages JeTaime and Luna22.
Microbiol Resour Announc
October 2021
The mycobacteriophages JeTaime (E cluster) and Luna22 (Q cluster) were isolated from soil in Providence, Rhode Island, and Charleston, South Carolina, respectively, using a Mycobacterium smegmatis mc 155 host. The genome of JeTaime is 75,099 bp (142 predicted genes), and that of Luna22 is 53,730 bp (87 predicted genes). Both phages exhibit morphology.
View Article and Find Full Text PDF